… Another major finding of the current study was that ADLL and ALL (but not ADL) slowed
disease progression when treatment was initiated before symptom onset, consistent with a …

… Another major finding of the current study was that ADLL and ALL (but not ADL) slowed
disease progression when treatment was initiated before symptom onset, consistent with a …

… and ALL (but not ADL) slowed disease progression when treatment was initiated before
symptom … as this actively contributes to disease progression and reducing inflammation using …

… disease is a rare neurodegenerative lysosomal storage disease associated with the storage
… but significantly extended lifespan and significantly slowed disease progression in Hexb -/- …

… The modified amino acid N-acetyl-leucine has been … , as well as slowing disease progression
and prolonging survival (… treatment of lysosomal storage disorders and neurodegenerative …

… The disease manifests with systemic, psychiatric, and … disease type C is currently limited to
slowing the progression of … for glycosphingolipid lysosomal storage disorders. Miglustat has …

… , slowed disease progression, and prolonged survival—… , disease-modifying effects of
acetyl-leucine were found in an analogous animal model of another lysosomal storage disease, …

… The modi ed amino acid N-acetyl-leucine has been … , as well as slowing disease progression
and prolonging survival (… treatment of lysosomal storage disorders and neurodegenerative …

… it is also a major risk factor for development of neurodegenerative diseases like Alzheimer’s
… effect in lysosomal storage disease patients, specially Niemann-Pick disease type C (Kaya …

… lysosomal storage disorders like Niemann-Pick disease type … have shown that N-acetyl-leucine
significantly reduced ataxia … , slowed disease progression, and prolonged survival. These …